Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Journal of Antimicrobial Chemotherapy

• Publication date

  2006-04-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1093/JAC/DKL022PMID 16464893
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Micafungin

  2012cited by this paper
• Pharmacokinetic and Maximum Tolerated Dose Study of Micafungin in Combination with Fluconazole versus Fluconazole Alone for Prophylaxis of Fungal Infections in Adult Patients Undergoing a Bone Marrow or Peripheral Stem Cell Transplant

  2005cited by this paper
• Specific Substitutions in the Echinocandin Target Fks1p Account for Reduced Susceptibility of Rare Laboratory and Clinical Candida sp. Isolates

  2005cited by this paper
• Multiechinocandin- and Multiazole-Resistant Candida parapsilosis Isolates Serially Obtained during Therapy for Prosthetic Valve Endocarditis

  2005cited by this paper
• A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients.

  2004cited by this paper
• A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis.

  2004cited by this paper
• Interlaboratory Comparison of Results of Susceptibility Testing with Caspofungin against Candida and Aspergillus Species

  2004cited by this paper
• Caspofungin Resistance in Candida albicans: Correlating Clinical Outcome with Laboratory Susceptibility Testing of Three Isogenic Isolates Serially Obtained from a Patient with Progressive Candida Esophagitis

  2004influential reference
• Further Standardization of Broth Microdilution Methodology for In Vitro Susceptibility Testing of Caspofungin against Candida Species by Use of an International Collection of More than 3,000 Clinical Isolates

  2004cited by this paper
• Collaborative Consensus for Optimized Multilocus Sequence Typing of Candida albicans

  2003cited by this paper
• Antifungal Susceptibility Survey of 2,000 Bloodstream Candida Isolates in the United States

  2003cited by this paper
• In vitro activity of three new triazoles and one echinocandin against Candida bloodstream isolates from cancer patients.

  2002cited by this paper
• Caspofungin versus amphotericin B for the treatment of Candidal esophagitis.

  2002cited by this paper
• Usefulness of Multilocus Sequence Typing for Characterization of Clinical Isolates of Candida albicans

  2002cited by this paper
• A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis.

  2001cited by this paper
• National Committee for Clinical Laboratory Standards.

  1980cited by this paper
• Drugs

  1967cited by this paper

• Pantothenate kinase is an effective target for antifungal therapy.

  2025cites this paper
• Early use of the novel antifungal rezafungin: a case series and literature review.

  2025cites this paper
• The yEvo Mutation Browser: Enhancing student understanding of experimental evolution and genomics through interactive data visualization

  2025cites this paper
• Confronting antifungal resistance, tolerance, and persistence: advances in drug target discovery and delivery systems.

  2023cites this paper
• Tackling the emerging threat of antifungal resistance to human health

  2022cites this paper
• Benzylic Dehydroxylation of Echinocandin Antifungal Drugs Restores Efficacy against Resistance Conferred by Mutated Glucan Synthase

  2022cites this paper
• Danish Whole-Genome-Sequenced Candida albicans and Candida glabrata Samples Fit into Globally Prevalent Clades

  2021cites this paper
• First report of antifungal activity of CecropinA-Magenin2 (CE-MA) hybrid peptide and its truncated derivatives.

  2021cites this paper
• Resistance to Antifungal Drugs.

  2021cites this paper
• Antifungal Susceptibility Testing: A Primer for Clinicians

  2021cites this paper
• The antifungal activity of caspofungin in combination with antifungals or non-antifungals against Candida species in vitro and in clinical therapy

  2021cites this paper
• Clonal evolution of Candida albicans, Candida glabrata and Candida dubliniensis at oral niche level in health and disease

  2021cites this paper
• Diutina (Candida) rugosa complex: The biofilm ultrastructure, extracellular matrix, cell wall component and antifungal susceptibility to amphotericin B, caspofungin, fluconazole and voriconazole

  2020cites this paper
• Fungal esophagitis

  2020cites this paper
• Antifungal Resistance Testing and Implications for Management

  2019cites this paper
• Facilitators of adaptation and antifungal resistance mechanisms in clinically relevant fungi.

  2019cites this paper
• Candida albicans rvs161Δ and rvs167Δ Endocytosis Mutants Are Defective in Invasion into the Oral Cavity

  2019cites this paper
• Systematic Classification of Antifungal Drugs, Resistance Mechanisms and Development of New Drugs

  2019influential citation
• AurH1: a new heptapeptide derived from Aurein1.2 antimicrobial peptide with specific and exclusive fungicidal activity

  2019cites this paper
• Candida Biofilm Tolerance: Comparison of Planktonic and Biofilm Resistance Mechanisms

  2017cites this paper
• Antimicrobial Drug Resistance

  2017influential citation
• A Review of Antifungal Peptides: Basis to New Era of Antifungal Drugs

  2016cites this paper
• Clonal Strain Persistence of Candida albicans Isolates from Chronic Mucocutaneous Candidiasis Patients

  2016cites this paper
• Parallel and cross-resistances of clinical yeast isolates determined by susceptibility pattern analysis

  2016cites this paper
• Candida albicans ribosome : structure, function, and inhibition

  2016cites this paper
• Echinocandin Resistance in Candida Species: a Review of Recent Developments

  2016cites this paper
• Antifungal drug resistance in pathogenic fungi

  2016cites this paper
• Mechanisms of Action of Antifungal Agents

  2015cites this paper
• The role of the FKS1 gene in nosocomial Candida albicans isolates' virulence and antifungal resistance

  2015influential citation
• Clinical perspectives on echinocandin resistance among Candida species

  2015cites this paper
• Clinical pharmacology of antifungal agents to overcome drug resistance in pediatric patients

  2015cites this paper
• Mónica Rodrigues Barbosa Evolution of antifungal drug resistance in Candida albicans Evolução de resistência a drogas em Candida albicans

  2015cites this paper
• Acquired Multidrug Antifungal Resistance in Candida lusitaniae during Therapy

  2015cites this paper
• Antifungal drug resistance among Candida species: mechanisms and clinical impact

  2015cites this paper
• Multidrug- and Cross-Resistant Candida: the Looming Threat

  2015cites this paper
• New echinocandin susceptibility patterns for nosocomial Candida albicans in Bogotá, Colombia, in ten tertiary care centres: an observational study

  2015influential citation
• Mechanisms of echinocandin antifungal drug resistance

  2015cites this paper
• Identification and strain typing of Candida albicans isolates from clinical samples

  2014cites this paper
• Emergence of echinocandin-resistant Candida spp. in a hospital setting: a consequence of 10 years of increasing use of antifungal therapy?

  2014cites this paper
• Molecular Characterization and In Vitro Antifungal Susceptibility of Candida Glabrata Clinical Isolates with Reduced Echinocandin Susceptibility and High Level Multi-Azole Resistance

  2014cites this paper
• Post-mortem analysis of Candida albicans breakthrough infection during echinocandin treatment in haematopoietic stem cell transplant recipient.

  2014cites this paper
• Echinocandin Resistance, Susceptibility Testing and Prophylaxis: Implications for Patient Management

  2014cites this paper
• Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations.

  2013cites this paper
• Design, Development, and Characterization of Novel Antimicrobial Peptides for Pharmaceutical Applications

  2013cites this paper
• Mechanisms of Candida biofilm drug resistance.

  2013cites this paper
• Rapid Emergence of Echinocandin Resistance during Candida kefyr Fungemia Treatment with Caspofungin

  2013cites this paper
• [Susceptibility to azoles and amphotericin B of isolates of Candida spp. Experience of a university health network, between 2004 and 2010].

  2012cites this paper
• Mechanisms of antifungal resistance in pathogenic yeasts: evaluation of the in vitro and in vivo expression

  2012cites this paper
• Mutants in the Candida glabrata Glycerol Channels Are Sensitized to Cell Wall Stress

  2012cites this paper
• Differential In Vivo Activities of Anidulafungin, Caspofungin, and Micafungin against Candida glabrata Isolates with and without FKS Resistance Mutations

  2012cites this paper
• Caspofungin for the Treatment of Immunocompromised and Severely Ill Children and Neonates with Invasive Fungal Infections

  2012cites this paper
• Fks1 and Fks2 Are Functionally Redundant but Differentially Regulated in Candida glabrata: Implications for Echinocandin Resistance

  2012cites this paper
• Stepwise Development of a Homozygous S80P Substitution in Fks1p, Conferring Echinocandin Resistance in Candida tropicalis

  2012cites this paper
• Particular Candida albicans Strains in the Digestive Tract of Dyspeptic Patients, Identified by Multilocus Sequence Typing

  2012cites this paper
• [Invasive candidiasis in a lung retransplantation recipient].

  2012cites this paper
• Caspofungin: when and how? The microbiologist’s view

  2012cites this paper
• Clinical Medicine insights: Pediatrics caspofungin for the Treatment of Immunocompromised and severely Ill children and neonates with Invasive Fungal Infections

  2012cites this paper
• Anidulafungin: when and how? The clinician’s view

  2012cites this paper
• Utility of Antifungal Susceptibility Testing and Clinical Correlations

  2012cites this paper
• Elevated Chitin Content Reduces the Susceptibility of Candida Species to Caspofungin

  2012cites this paper
• Antifungal therapy for newborn infants with invasive fungal infection.

  2012cites this paper
• Micafungin

  2012cites this paper
• Evaluation of Caspofungin Susceptibility Testing by the New Vitek 2 AST-YS06 Yeast Card Using a Unique Collection of FKS Wild-Type and Hot Spot Mutant Isolates, Including the Five Most Common Candida Species

  2012cites this paper
• Interactions of Yeasts, Moulds, and Antifungal Agents

  2012cites this paper
• Candidiasis invasora en una paciente sometida a retrasplante unipulmonar

  2012cites this paper
• Candida and candidiasis in HIV-infected patients: where commensalism, opportunistic behavior and frank pathogenicity lose their borders

  2012cites this paper
• Development of Echinocandin Resistance in Clavispora lusitaniae during Caspofungin Treatment

  2011cites this paper
• EUCAST technical note on anidulafungin.

  2011cites this paper
• Acquired antifungal drug resistance in Aspergillus fumigatus: epidemiology and detection.

  2011cites this paper
• Regulatory Circuitry Governing Fungal Development, Drug Resistance, and Disease

  2011influential citation
• Elevated Cell Wall Chitin in Candida albicans Confers Echinocandin Resistance In Vivo

  2011cites this paper
• Caspofungin Dose Escalation for Invasive Candidiasis Due to Resistant Candida albicans

  2011cites this paper
• Fungal Drug Resistance and Pharmacologic Considerations of Dosing Newer Antifungal Therapies

  2011cites this paper
• Rôle de la voie de signalisation MAP kinase Mps1 dans la pathogénie fongique et dans le contrôle de l'intégrité de la paroi

  2011cites this paper
• Comparison of CLSI broth macrodilution and microdilution methods for echinocandin susceptibility testing of 5 Candida species.

  2011cites this paper
• The value of amphotericin B in the treatment of invasive fungal infections.

  2011cites this paper
• Definitions and Epidemiology of Candida Species not Susceptible to Echinocandins

  2011cites this paper
• linical breakpoints for the echinocandins and Candida revisited : Integration of olecular , clinical , and microbiological data to arrive at species-specific nterpretive criteria

  2011cites this paper
• Management of invasive fungal infections: a role for polyenes.

  2011cites this paper
• Anidulafungin: Review of its Role in the Treatment of Invasive Candidiasis

  2011cites this paper
• Fitness and virulence costs of Candida albicans FKS1 hot spot mutations associated with echinocandin resistance.

  2011cites this paper
• Pharmacology and metabolism of anidulafungin, caspofungin and micafungin in the treatment of invasive candidosis - review of the literature

  2011cites this paper
• Use of Pharmacokinetic-Pharmacodynamic Analyses To Optimize Therapy with the Systemic Antifungal Micafungin for Invasive Candidiasis or Candidemia

  2011cites this paper
• In Vivo albicans Confers Echinocandin Resistance Elevated Cell Wall Chitin in Candida

  2011cites this paper
• Epidemiology and treatment approaches in management of invasive fungal infections

  2011influential citation
• Epidemiology and antifungal resistance in invasive candidiasis

  2011cites this paper
• Evaluation of CLSI M44-A2 Disk Diffusion and Associated Breakpoint Testing of Caspofungin and Micafungin Using a Well-Characterized Panel of Wild-Type and fks Hot Spot Mutant Candida Isolates

  2011cites this paper
• Echinocandin Susceptibility Testing of Candida Isolates Collected during a 1-Year Period in Sweden

  2011cites this paper
• Echinocandin Susceptibility Testing of Candida spp. Using EUCAST EDef 7.1 and CLSI M27-A3 Standard Procedures: Analysis of the Influence of Bovine Serum Albumin Supplementation, Storage Time, and Drug Lots

  2011cites this paper
• Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria.

  2011cites this paper
• Molecular Detection of Antifungal Resistance

  2011cites this paper
• FKS Mutations and Elevated Echinocandin MIC Values among Candida glabrata Isolates from U.S. Population-Based Surveillance

  2010cites this paper
• Clinically significant micafungin resistance in Candida albicans involves modification of a glucan synthase catalytic subunit GSC1 (FKS1) allele followed by loss of heterozygosity.

  2010cites this paper
• Antifungal Drug Resistance in Developing Countries

  2010cites this paper
• Echinocandins – Caspofungin, Anidulafungin and Micafungin

  2010cites this paper
• Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods.

  2010cites this paper
• Breakthrough Invasive Candidiasis in Patients on Micafungin

  2010cites this paper
• Approaches to the early treatment of invasive fungal infection

  2010cites this paper
• Novel FKS Mutations Associated with Echinocandin Resistance in Candida Species

  2010cites this paper
• Antimicrobial drug resistance is an obstacle to the treatment of numerous infectious diseases

  2010cites this paper